Application
Fig1: Western blot analysis of BCR on human BCR recombinant protein using anti-BCR antibody at 1/1,000 dilution.Application
Fig2: Western blot analysis of BCR on HEK293 (1) and BCR-hIgGFc transfected HEK293 (2) cell lysate using anti-BCR antibody at 1/1,000 dilution.Application
Fig3: Western blot analysis of BCR on different cell lysate using anti-BCR antibody at 1/1,000 dilution. Positive control： Line1: Jurkat Line2: Hela Line3: RamosApplication
Fig4: Flow cytometric analysis of K562 cells with BCR antibody at 1/100 dilution (green) compared with an unlabelled control (cells without incubation with primary antibody; red).| Product Name | BCR [G12-E11] |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | ALL antibody bcr antibody BCR/ABL FUSION GENE, INCLUDED antibody BCR/FGFR1 chimera protein antibody BCR/FGFR1 FUSION GENE, INCLUDED antibody BCR/PDGFRA FUSION GENE, INCLUDED antibody BCR_HUMAN antibody BCR1 antibody Breakpoint cluster region antibody Breakpoint cluster region protein antibody CML antibody D22S11 antibody D22S662 antibody FGFR1/BCR chimera protein antibody PHL antibody Renal carcinoma antigen NY-REN-26 antibody |
| Product description | The Bcr gene, mapping on chromosome 22, was initially identified on the basis of its fusion with the c-Abl proto-oncogene on chromosome 9 resulting in the generation of the Philadelphia chromosome in 90-95% of patients with chronic myelogenous leukemia (CML). The Bcr gene encodes for the breakpoint cluster region (Bcr) protein. A consequence of this translocation is the generation of a Bcr/c-Abl mRNA encoding an activated c-Abl protein kinase. The Bcr gene has been shown to encode a GTPase-activating protein (GAP) specific for the Ras-related GTP-binding protein, Rac 1 p21. While it has been speculated that the Bcr protein may also stimulate Rac 2 p21 GTPase activity, it has no effect on Ras p21 or Rho p21 GTPases. It is of interest that the GAP domain of Bcr maps outside of the region that remains on chromosome 22 (Philadelphia chromosome) in CML. |
| Immunogen | Recombinant protein |
| Clonality | Monoclonal |
|---|---|
| Isotype | IgG1 |
| Host Species | Mouse |
| Tested Applications | WBFC |
| WB:1:500-1:2,000 FC:1:50-1:100 |
|
| Species Reactivity | Human |
| Concentration | 2mg/ml |
| Alternative Names | ALL antibody
bcr antibody
BCR/ABL FUSION GENE INCLUDED antibody BCR/FGFR1 chimera protein antibody BCR/FGFR1 FUSION GENE INCLUDED antibody BCR/PDGFRA FUSION GENE INCLUDED antibody BCR_HUMAN antibody BCR1 antibody Breakpoint cluster region antibody Breakpoint cluster region protein antibody CML antibody D22S11 antibody D22S662 antibody FGFR1/BCR chimera protein antibody PHL antibody Renal carcinoma antigen NY-REN-26 antibody |
|---|---|
| Molecular Weight(MW) | 143 kDa |
| Cellular Localization | Cell junction, synapse, postsynaptic density. |
| SwissProt ID | P11274 |
|---|
Application
Fig1: Western blot analysis of BCR on human BCR recombinant protein using anti-BCR antibody at 1/1,000 dilution.
Application
Fig2: Western blot analysis of BCR on HEK293 (1) and BCR-hIgGFc transfected HEK293 (2) cell lysate using anti-BCR antibody at 1/1,000 dilution.
Application
Fig3: Western blot analysis of BCR on different cell lysate using anti-BCR antibody at 1/1,000 dilution. Positive control： Line1: Jurkat Line2: Hela Line3: Ramos
Application
Fig4: Flow cytometric analysis of K562 cells with BCR antibody at 1/100 dilution (green) compared with an unlabelled control (cells without incubation with primary antibody; red).| Positive Control | Human BCR recombinant protein, BCR-hIgGFc transfected HEK293 cell lysate, Jurkat, Hela, Ramos cell lysate, K562. |
|---|---|
| Application Notes | WB:1:500-1:2,000 FC:1:50-1:100 |
| Form | Liquid |
|---|---|
| Storage Instructions | Store at +4℃ after thawing. Aliquot store at -20℃ or -80℃. Avoid repeated freeze / thaw cycles. |
| Storage Buffer | 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide. |
